Trial Profile
Phase II Randomised Controlled Trial to Evaluate Safety and Immunogenicity of MVA85A and Selective, Delayed Bacille Calmette-Guerin Vaccination in Infants of HIV Infected Mothers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs BCG vaccine (Primary) ; MVA 85A (Primary) ; Candida antigen
- Indications Tuberculosis
- Focus Adverse reactions; Biomarker
- Acronyms MVA(TB)029
- 26 Sep 2017 Results published in the Clinical Infectious Diseases
- 30 Jan 2013 Planned initiation date is 1 Oct 2012 as identified on ClinicalTrials.gov.
- 30 Jan 2013 Status changed from not yet recruiting to recruiting according to the ClinicalTrials.gov.